Paradigm Biopharmaceuticals Ltd Market Cap ($91.09 Million)
Market Cap & Net Worth: Paradigm Biopharmaceuticals Ltd (PAR)
Paradigm Biopharmaceuticals Ltd market cap. Paradigm Biopharmaceuticals Ltd (AU:PAR) has a market capitalization of $91.09 Million (AU$128.74 Million) as of November 8, 2026. Listed on the AU stock exchange, this Australia-based company holds position #19321 globally and #619 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Paradigm Biopharmaceuticals Ltd's stock price AU$0.25 by its total outstanding shares 525456672 (525.46 Million). Also see Paradigm Biopharmaceuticals Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Paradigm Biopharmaceuticals Ltd Market Cap History (2015–2026)
Paradigm Biopharmaceuticals Ltd market cap history from 2015 to 2026. Data shows change from $119.83 Million to $91.09 Million (-1.61% CAGR). Check Paradigm Biopharmaceuticals Ltd stock price for real-time trading data and today's change.
Index Memberships
Paradigm Biopharmaceuticals Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$2.04 Trillion | 0.00% | #303 of 495 |
Weight: Paradigm Biopharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Paradigm Biopharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Paradigm Biopharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PAR net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2425.36x
Paradigm Biopharmaceuticals Ltd's market cap is 2425.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $141.62 Million | $1.29 Million | -$2.92 Million | 109.73x | N/A |
| 2017 | $101.65 Million | $1.82 Million | -$4.28 Million | 55.76x | N/A |
| 2018 | $381.24 Million | $2.68 Million | -$6.19 Million | 142.09x | N/A |
| 2019 | $1.09 Billion | $2.98 Million | -$15.63 Million | 365.07x | N/A |
| 2020 | $948.07 Million | $4.70 Million | -$12.30 Million | 201.91x | N/A |
| 2021 | $700.83 Million | $20.55K | -$34.30 Million | 34103.74x | N/A |
| 2022 | $522.37 Million | $79.22K | -$39.25 Million | 6593.59x | N/A |
| 2023 | $158.01 Million | $46.76K | -$51.91 Million | 3379.22x | N/A |
| 2024 | $139.42 Million | $65.80K | -$58.65 Million | 2118.89x | N/A |
| 2025 | $126.41 Million | $52.12K | -$18.77 Million | 2425.36x | N/A |
Competitor Companies of PAR by Market Capitalization
Companies near Paradigm Biopharmaceuticals Ltd in the global market cap rankings as of November 8, 2026. Also see Paradigm Biopharmaceuticals Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Paradigm Biopharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Paradigm Biopharmaceuticals Ltd (2015–2026)
Market capitalization of Paradigm Biopharmaceuticals Ltd from 2015 to today. Between 2015 and today, Paradigm Biopharmaceuticals Ltd's market cap moved from $119.83 Million to $ 91.09 Million, with a yearly change of -1.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$91.09 Million | -27.94% |
| 2025 | AU$126.41 Million | -9.33% |
| 2024 | AU$139.42 Million | -11.76% |
| 2023 | AU$158.01 Million | -69.75% |
| 2022 | AU$522.37 Million | -25.46% |
| 2021 | AU$700.83 Million | -26.08% |
| 2020 | AU$948.07 Million | -12.97% |
| 2019 | AU$1.09 Billion | +185.74% |
| 2018 | AU$381.24 Million | +275.05% |
| 2017 | AU$101.65 Million | -28.22% |
| 2016 | AU$141.62 Million | +18.18% |
| 2015 | AU$119.83 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Paradigm Biopharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $91.09 Million USD |
| MoneyControl | $91.09 Million USD |
| MarketWatch | $91.09 Million USD |
| marketcap.company | $91.09 Million USD |
| Reuters | $91.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more